BRIEF-Novo Selects Gefion AI Supercomputer To Advance Drug Discovery, Innovation

Dow Jones Industrial Average -0.24%
S&P 500 index -0.21%
NASDAQ -0.35%

Dow Jones Industrial Average

DJI

47794.20

-0.24%

S&P 500 index

SPX

6768.40

-0.21%

NASDAQ

IXIC

22556.41

-0.35%

June 11 (Reuters) - Novo Nordisk A/S NOVOb.CO:

  • NOVO NORDISK SELECTS GEFION AI SUPERCOMPUTER TO ADVANCE DRUG DISCOVERY AND HEALTHCARE INNOVATION

  • WILL GAIN ACCESS TO GEFION'S COMPUTATIONAL CAPABILITIES TO PROCESS VAST DATASETS

  • NOVO NORDISK HAS MADE AI A STRATEGIC FOCUS ACROSS ITS VALUE CHAIN AND GEFION WILL PLAY A KEY ROLE IN EXECUTION OF THESE COMPUTE-INTENSIVE PROJECTS

  • PARTIES SIGN MULTIYEAR AGREEMENT

Source text: ID:nPn72FmT4a

Further company coverage: [NOVOb.CO]


(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.